These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29172970)

  • 1. Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints.
    Jiang W; Wick JA; He J; Mahnken JD; Mayo MS
    J Biopharm Stat; 2018; 28(5):824-839. PubMed ID: 29172970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generalized optimal design for two-arm, randomized phase II clinical trials with endpoints from the exponential dispersion family.
    Jiang W; Mahnken JD; He J; Mayo MS
    Pharm Stat; 2016 Nov; 15(6):459-470. PubMed ID: 27511063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
    Sambucini V
    J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian optimal phase II clinical trial design with time-to-event endpoint.
    Zhou H; Chen C; Sun L; Yuan Y
    Pharm Stat; 2020 Nov; 19(6):776-786. PubMed ID: 32524679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
    Zhao L; Woodworth G
    Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal designs for two-arm, phase II clinical trial design with multiple constraints.
    Mayo MS; Mahnken JD; Soong SJ
    J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints.
    Cotterill A; Whitehead J
    Stat Med; 2015 May; 34(11):1889-903. PubMed ID: 25620687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical inference for response adaptive randomization procedures with adjusted optimal allocation proportions.
    Zhu H
    J Biopharm Stat; 2017; 27(5):732-740. PubMed ID: 27937121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
    Zhou H; Lee JJ; Yuan Y
    Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
    Moatti M; Chevret S; Zohar S; Rosenberger WF
    Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian monitoring of phase II trials in cancer chemoprevention.
    Cronin KA; Freedman LS; Lieberman R; Weiss HL; Beenken SW; Kelloff GJ
    J Clin Epidemiol; 1999 Aug; 52(8):705-11. PubMed ID: 10465313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
    Johnson VE; Cook JD
    Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
    Lai X; Zee BC
    Trials; 2015 Jun; 16():250. PubMed ID: 26037094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint.
    Huang B; Talukder E; Han L; Kuan PF
    J Biopharm Stat; 2019; 29(1):189-202. PubMed ID: 29969380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups.
    Yin J; Qin R; Sargent DJ; Erlichman C; Shi Q
    J Biopharm Stat; 2018; 28(3):451-462. PubMed ID: 28448747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of adaptive designs for single-armed phase II oncology trials.
    Kieser M; Englert S
    J Biopharm Stat; 2015; 25(3):602-15. PubMed ID: 24905363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal two-stage designs for single-arm phase II oncology trials with two binary endpoints.
    Kunz CU; Kieser M
    Methods Inf Med; 2011; 50(4):372-7. PubMed ID: 21057719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.